Home

  Better poultry production practices in Yangon Poultry Production Zones | FAO in Myanmar | Organizaci

The country is at risk for zoonotic avian influenza A (H7N9) virus incursion. Furthermore, active surveillance in live bird markets regularly detects H5N1 and H5N6 HPAI viruses and low pathogenic avian influenza (LPAI) H9N2 viruses. (...) However, vaccination for avian influenza is not permitted by law in Myanmar. A nationwide survey on H9 antibodies in chicken eggs was conducted to provide evidence on H9 avian influenza distribution. (...) All States/Regions had H9 antibody-positive eggs (range from 24% to 86%) providing strong evidence that H9 avian influenza viruses are widely distributed. The results of the survey support LBVD decision-making on avian influenza vaccination policy.

Score: 1471334.1 - https://www.fao.org/myanmar/pr.../poultry-production-yangon/es/

  Better poultry production practices in Yangon Poultry Production Zones | FAO in Myanmar | Food and A

The country is at risk for zoonotic avian influenza A (H7N9) virus incursion. Furthermore, active surveillance in live bird markets regularly detects H5N1 and H5N6 HPAI viruses and low pathogenic avian influenza (LPAI) H9N2 viruses. (...) However, vaccination for avian influenza is not permitted by law in Myanmar. A nationwide survey on H9 antibodies in chicken eggs was conducted to provide evidence on H9 avian influenza distribution. (...) All States/Regions had H9 antibody-positive eggs (range from 24% to 86%) providing strong evidence that H9 avian influenza viruses are widely distributed. The results of the survey support LBVD decision-making on avian influenza vaccination policy.

Score: 1471334.1 - https://www.fao.org/myanmar/pr.../poultry-production-yangon/en/

  Sustaining local influenza vaccine production in Serbia

The journey began in 2009, when the institute was selected as a technology transfer grantee under the Global Action Plan for Influenza Vaccines (GAP) to increase the global availability and equitable access to influenza vaccines in the event of a pandemic. Under GAP, the Torlak Institute received technical and financial support from a range of international partners and the Serbian government to refurbish its influenza vaccine manufacturing facility, establish a modern process for influenza vaccine production, and design and implement clinical trials. (...) This sustainability assessment identified priorities for action, including: updating the national seasonal influenza vaccination policy based on current evidence; strengthening the business case for local production, including increasing domestic demand and seeking opportunities for export; strengthening vaccine distribution and logistics; creating new seasonal influenza vaccination campaigns; and emphasizing the Torlak Institute’s role within the national influenza pandemic preparedness plan.

Score: 1469159.8 - https://www.who.int/news/item/...a-vaccine-production-in-serbia

  Microsoft Word - Stmt on AI for ECOSOC 11-03press.doc

Representative to the Economic and Social Council: Special Event on Avian Influenza November 3, 2005 Thank you Mr President for hosting this meeting on the very urgent issue of preparing for the possibility of an influenza pandemic. (...) Over the past year, we have also provided $5.5 million in technical assistance and grants to affected areas in Southeast Asia and to the World Health Organization (WHO) for influenza pandemic preparedness. In his address to the General Assembly on September 14, 2005, President Bush spoke to the dangers of avian influenza, and launched the International Partnership on Avian and Pandemic Influenza (IPAPI). (...) In its first meeting of senior officials in Washington, October 6-7, the partnership identified the need for further work on issues of stockpiles, response and containment, and vaccine development, production capacity and distribution. Establishing clear protocols for when and how the international community would intervene to try to contain incipient human-to-human transmission of H5N1 or a similar strain was a key element of the discussions at the Global Pandemic Influenza Readiness meeting in Ottawa, October 24-25.

Score: 1468185.1 - https://www.un.org/ecosoc/site...05_avian_flu_united_states.pdf

  Medical Product Alert N°5/2020

Select language Select language English العربية 中文 Français Русский Español Português Home Health Topics All topics » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Resources » Fact sheets Facts in pictures Multimedia Publications Questions & answers Tools and toolkits Popular » Air pollution Coronavirus disease (COVID-19) Hepatitis Monkeypox Countries All countries » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Regions » Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific WHO in countries » Statistics Cooperation strategies Ukraine emergency Newsroom All news » News releases Statements Campaigns Commentaries Events Feature stories Speeches Spotlights Newsletters Photo library Media distribution list Headlines » Emergencies Focus on » Afghanistan crisis COVID-19 pandemic Northern Ethiopia crisis Syria crisis Ukraine emergency Monkeypox outbreak Greater Horn of Africa crisis Latest » Disease Outbreak News Travel advice Situation reports Weekly Epidemiological Record WHO in emergencies » Surveillance Research Funding Partners Operations Independent Oversight and Advisory Committee Data Data at WHO » Global Health Estimates Health SDGs Mortality Database Data collections Dashboards » COVID-19 Dashboard Triple Billion Dashboard Health Inequality Monitor Highlights » Global Health Observatory SCORE Insights and visualizations Data collection tools Reports » World Health Statistics 2022 COVID excess deaths DDI IN FOCUS: 2022 About WHO About WHO » People Teams Structure Partnerships and collaboration Collaborating centres Networks, committees and advisory groups Transformation Our Work » General Programme of Work WHO Academy Activities Initiatives Funding » Investment case WHO Foundation Accountability » Audit Budget Financial statements Programme Budget Portal Results Report Governance » World Health Assembly Executive Board Election of Director-General Governing Bodies website Home / News / item / Medical Product Alert N°6/2020: Falsified Fluzone® Quadrivalent Influenza Vaccine Medical Product Alert N°6/2020: Falsified Fluzone® Quadrivalent Influenza Vaccine Falsified Fluzone® Quadrivalent Influenza Vaccine identified in WHO region of the Americas 30 October 2020 Medical product alert Geneva Reading time: Falsified Fluzone® Quadrivalent Influenza Vaccine identified in WHO region of the Americas Alert Summary This WHO Medical Product Alert relates to three different batches of confirmed falsified Fluzone® Quadrivalent Influenza Vaccine identified in Mexico and reported to WHO on 16 October 2020. Fluzone® Quadrivalent is a quadrivalent inactivated vaccine for immunization against influenza A virus (H1N1 and H3N2) and B subtypes. The products subject of this alert are confirmed falsified because they deliberately/fraudulently misrepresent their identity, composition or source: The genuine manufacturer of Fluzone® Quadrivalent - Sanofi Pasteur – has confirmed they did not produce or distribute the products subject of this WHO Medical Product Alert n°6/2020, AND the variable data (batch number and expiry dates) of these products do not correspond to their genuine manufacturing records. (...) On 21 September 2020, the WHO Strategic Advisory Group of Experts (SAGE) on immunization highlighted [1] that health workers and older adults are considered as the highest priority risk groups to receive influenza vaccines during the COVID-19 pandemic. It is therefore crucial to identify, as early as possible, any falsified influenza vaccines in circulation.

Score: 1467752.3 - https://www.who.int/news/item/...medical-product-alert-n-6-2020

  Global Influenza Programme

About Vaccines Section navigation Recommendations for influenza vaccine composition Seasonal influenza candidate vaccine viruses Zoonotic influenza candidate vaccine viruses Vaccine use Vaccine in tropics and subtropics Influenza Vaccination Toolbox Guidance and technical resources  Global Influenza Programme Vaccination is the most effective way to prevent infection and severe outcomes caused by influenza viruses. (...) For more than 50 years, WHO has been collaborating with scientists and policy makers on a global scale to develop a unified approach to manufacturing, testing and regulatory oversight of influenza vaccine development as well as their efficient use and distribution.   (...) The constantly evolving nature of influenza viruses requires continuous global monitoring and frequent reformulation of influenza vaccines.

Score: 1453705.5 - https://www.who.int/teams/glob...l-influenza-programme/vaccines

  FAO H7N9 documents, library - Avian Influenza A(H7N9) virus - FAO Emergency Prevention System for An

FAO H7N9 documents, library - Avian Influenza A(H7N9) virus - FAO Emergency Prevention System for Animal Health (EMPRES-AH) Home Themes Programmes/projects Partners Resources Print this page | Close Programmes/projects Emergency Prevention System for Animal Health (EMPRES-AH) Transboundary Animal Diseases (TADs) Influenza A(H7N9) virus Background H7N9 situation update Virology Diagnostic tests and vaccines Surveillance and control in animals FAO recommendations FAO actions FAQs Media releases Documents Links H7N9 Documents Risk guidelines on avian influenza A(H7N9)   H7N9 Guidelines for emergency risk-based surveillance - June 2013 H7N9 Surveillance guidelines for uninfected countries in Southeast Asia and South Asia - November 2013 H7N9 Guidelines for risk communication messaging H7N9 Risk management along the food chain H7N9 Laboratory protocols and algorithms     Risk assessments on avian influenza A(H7N9)   H7N9 Emergency risk assessment summary - June 2013 H7N9 Qualitative risk assessment update - January 2014 H7N9 Qualitative risk assessment update - April 2014 Chinese-origin H7N9 Highly Pathogenic Avian Influenza: Risk Assessment      Biosecurity   Biosecurity guide for live poultry markets Biosecurity for Highly Pathogenic Avian Influenza ECTAD brochure on biosecurity    Management   Preparing for Highly Pathogenic Avian Influenza Good Emergency Management Practice: The Essentials Regulatory Frameworks for Control of HPAI and Other TADs Lessons from HPAI Economic analysis of animal diseases    Miscellaneous   Highly pathogenic H5 avian influenza in 2016 and early 2017 - Observations and future perspectives Rational use of vaccination for control and prevention of H5 highly pathogenic avian influenza Avian influenza A(H5N6): the latest addition to emerging zoonotic avian influenza threats in East and Southeast Asia Spatial Distribution and Risk Factors of Highly Pathogenic Avian Influenza (HPAI) H5N1 in China      Value Chain   A Value Chain Approach to Animal Diseases Risk Management: Technical Foundations and Practical Framework for Field Application Designing and Implementing Livestock Value Chain Studies      Wild birds   Wild bird Highly Pathogenic Avian Influenza Surveillance Wild Bird and Avian Influenza Comments: EMPRES-Animal Health © FAO ,

Score: 1449906.9 - https://www.fao.org/ag/againfo.../en/empres/H7N9/Documents.html

  2022 – Celebrating 70 years of GISRS (the Global Influenza Surveillance and Response System)

GISRS is a proven global network that has provided a first line of defence against influenza for 70 years. WHO Director-General, Dr Tedros Adhanom Ghebreyesus   Influenza is a serious global health problem that impacts all countries: every year, there are an estimated one billion cases of seasonal Influenza causing three to five million severe cases including up to 650 000 influenza-related respiratory deaths globally. (...) GISRS members share around 20 000 influenza virus samples every year to WHO CCs and regularly update the weekly influenza situation based on laboratory and disease surveillance reporting through the FluNet and FluID systems, thus allowing WHO to distribute timely risk assessments and alerts to countries. (...) Although GISRS was built to address influenza, it also serves as a critical resource for countries handling non-influenza emergencies.

Score: 1444890 - https://www.who.int/news/item/...veillance-and-response-system)

  Celebrating 70 years of GISRS (the Global Influenza Surveillance and Response System)

GISRS is a proven global network that has provided a first line of defence against influenza for 70 years. WHO Director-General, Dr Tedros Adhanom Ghebreyesus   Influenza is a serious global health problem that impacts all countries: every year, there are an estimated one billion cases of seasonal Influenza causing three to five million severe cases including up to 650 000 influenza-related respiratory deaths globally. (...) GISRS members share around 20 000 influenza virus samples every year to WHO CCs and regularly update the weekly influenza situation based on laboratory and disease surveillance reporting through the FluNet and FluID systems, thus allowing WHO to distribute timely risk assessments and alerts to countries. (...) Although GISRS was built to address influenza, it also serves as a critical resource for countries handling non-influenza emergencies.

Score: 1444890 - https://www.who.int/news/item/...veillance-and-response-system)

  Partnership contribution

The Partnership Contribution (PC) is one element of the Pandemic Influenza Preparedness (PIP) Framework Benefit Sharing System. It is an annual cash contribution of US$ 28 million given to WHO by influenza vaccine, diagnostic and pharmaceutical manufacturers that use the WHO Global Influenza Surveillance and Response System (GISRS). (...) Learn more about GISRS 26 March 2015 WHO: PIP Framework - Partnership Contribution PC Collection & Implementation Every year WHO issues an annual questionnaire that identifies potential contributors. It is distributed to existing contributors, to all companies and institutions that conduct research and development in the field of influenza, and to all recipients of PIP biological material recorded in the Influenza Virus Traceability Mechanism (IVTM) database . 

Score: 1427951 - https://www.who.int/initiative...ework/partnership-contribution